PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

13 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

    J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

    The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 NUXudI9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLtTWM2OD1yLkCyNlc3KM7:TR?= NVHaeIZxW0GQR1XS
CHP-212 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjnflVKSzVyPUCuNFI5QDVizszN MnjLV2FPT0WU
EoL-1-cell NUHqNnF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:xb5RKSzVyPUCuNFQyPTJizszN Mof6V2FPT0WU
DU-4475 NV\LUIJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzueZVKSzVyPUCuNFc2QTlizszN NGr3bnRUSU6JRWK=
MMAC-SF NUK3b2FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rlSGlEPTB;MD6xNFk4PCEQvF2= NFG0So1USU6JRWK=
AGS M3fWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMUG3NVMh|ryP M3XzNHNCVkeHUh?=
M14 NFHjNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTjSld[UUN3ME2wMlE2PDZ6IN88US=> MkixV2FPT0WU
CP50-MEL-B MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMUeyOVQh|ryP MYHTRW5ITVJ?
C32 MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle2TWM2OD1yLkG5NFczKM7:TR?= NWrsc|BVW0GQR1XS
KMOE-2 M4jMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGxTWM2OD1yLkG5O|k2KM7:TR?= NFf4b5BUSU6JRWK=
A101D NVmzfFJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[5TWM2OD1yLkKxOEDPxE1? MVfTRW5ITVJ?
KM12 NEnyXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P5OmlEPTB;MD6yOFA2PyEQvF2= MYfTRW5ITVJ?
HSC-4 NXXocG55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2iwNGlEPTB;MD6yOFM6PSEQvF2= M130dHNCVkeHUh?=
NOMO-1 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PVZ2lEPTB;MD6yOVc1OiEQvF2= MX\TRW5ITVJ?
MZ7-mel M2TjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;jZmlEPTB;MD6yOlM1KM7:TR?= NI[4XYpUSU6JRWK=
ACN NYfqdJNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYezbFA6UUN3ME2wMlI3PzN5IN88US=> MoLuV2FPT0WU
MEL-HO NH3Pd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfGTWM2OD1yLkK3OlUzKM7:TR?= M{jrfHNCVkeHUh?=
BHT-101 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD4PIlsUUN3ME2wMlI5PjB4IN88US=> NH22PZdUSU6JRWK=
SK-MEL-28 NXP2[m9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml73TWM2OD1yLkOwOFA6KM7:TR?= MUjTRW5ITVJ?
KG-1 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwM{C2Olgh|ryP MmLNV2FPT0WU
COLO-679 NYLETm9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[xTWM2OD1yLkOyO|Ih|ryP M4TCVnNCVkeHUh?=
SK-MEL-24 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjaepdKSzVyPUCuN|I5OTNizszN M{\rVXNCVkeHUh?=
G-361 M2LGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PKTWlEPTB;MD6zOlc6PSEQvF2= NEH2[|FUSU6JRWK=
KY821 NXXJPWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwM{e5NUDPxE1? M1PZVHNCVkeHUh?=
KASUMI-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\iOYpPUUN3ME2wMlM6QSEQvF2= NUTYXFVLW0GQR1XS
HL-60 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GxZWlEPTB;MD60NVExPyEQvF2= NY\DOoZzW0GQR1XS
K5 NI\FN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPLTZpKSzVyPUCuOFMyOTdizszN NXv5ZlZwW0GQR1XS
KU812 NXPyVXh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOxTWM2OD1yLkS1Nlk6KM7:TR?= MUXTRW5ITVJ?
SH-4 NFHEVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNE[yOVYh|ryP M3\RW3NCVkeHUh?=
HTC-C3 MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX64TpJIUUN3ME2wMlQ3PTNzIN88US=> MWjTRW5ITVJ?
CP66-MEL MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO2TWM2OD1yLkS4PFA6KM7:TR?= M1Ozd3NCVkeHUh?=
WM-115 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzsTWM2OD1yLkS5NlU4KM7:TR?= M{PHT3NCVkeHUh?=
A2780 NGmwW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXXTWM2OD1yLkS5PFI{KM7:TR?= MVrTRW5ITVJ?
P12-ICHIKAWA M3:0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInJTGpKSzVyPUCuOlEzOjFizszN MnvNV2FPT0WU
HMV-II NY\qeoR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjyeWZKSzVyPUCuOlQ1PjVizszN M3ewfXNCVkeHUh?=
HT-144 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHrTWM2OD1yLk[0OlU4KM7:TR?= NFqzSG5USU6JRWK=
LB2518-MEL Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwN{G2N|Ih|ryP MmrJV2FPT0WU
NCI-SNU-1 M4nQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwN{W0N|Mh|ryP MmDkV2FPT0WU
C2BBe1 NULZSIVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHIWZVVUUN3ME2wMlgyODJ|IN88US=> M3;MUnNCVkeHUh?=
PSN1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwOU[xPVYh|ryP MV;TRW5ITVJ?
UACC-257 NWTEOoRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwOU[0O|Mh|ryP NIDNNIlUSU6JRWK=
RVH-421 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnixTWM2OD1yLkm3NVgh|ryP M4PIdnNCVkeHUh?=
GP5d NUH1fWllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFThVnpKSzVyPUCuPVg{ODhizszN MUnTRW5ITVJ?
TYK-nu NEXnS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LqcGlEPTB;MT6wN|E4OiEQvF2= MnrSV2FPT0WU
SK-N-AS NG\DZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37vVWlEPTB;MT6wO|k1PyEQvF2= MVXTRW5ITVJ?
SW620 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j6NmlEPTB;MT6xN|U{PCEQvF2= MUTTRW5ITVJ?
HuP-T4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnFTWM2OD1zLkG4N|U6KM7:TR?= NVflbnZiW0GQR1XS
A549 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDsXI5KSzVyPUGuNVk2PzZizszN MULTRW5ITVJ?
Mewo MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXMXHFKSzVyPUGuNlAzPzZizszN MV;TRW5ITVJ?
ONS-76 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i0OWlEPTB;MT6yNlA1QSEQvF2= MkPmV2FPT0WU
SK-MEL-1 M1nITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\6OINXUUN3ME2xMlI{PDF7IN88US=> NFm0NHpUSU6JRWK=
RCM-1 NFHTeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LLeWlEPTB;MT6yOFA1PyEQvF2= NEDLNlhUSU6JRWK=
H-EMC-SS NW[0dodHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjzTWM2OD1zLkK5OlA5KM7:TR?= NYPoNos{W0GQR1XS
NCI-H2291 NFPLPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\aTWM2OD1zLkOyOVM3KM7:TR?= M13ze3NCVkeHUh?=
SW1463 M1HYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP6dXg4UUN3ME2xMlM{PzJzIN88US=> NXXWU4ZiW0GQR1XS
LS-411N MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr6R2FKSzVyPUGuOFA2OTdizszN MoTKV2FPT0WU
BV-173 MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrGfVBwUUN3ME2xMlQ1ODF3IN88US=> MmD2V2FPT0WU
LS-513 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwNEWxPVIh|ryP Mnv0V2FPT0WU
LoVo M4H4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfmTWM2OD1zLkS2N|k6KM7:TR?= MkHSV2FPT0WU
HO-1-N-1 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFwNUG2N|Qh|ryP NFvre4lUSU6JRWK=
ML-2 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LCUWlEPTB;MT61Nlg3QCEQvF2= NYrZWoN3W0GQR1XS
NCI-H1437 NUT3RlEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjUTWM2OD1zLkW1Nlc2KM7:TR?= MULTRW5ITVJ?
SW1116 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17obGlEPTB;MT61OlM6QCEQvF2= M{nFenNCVkeHUh?=
A4-Fuk M2nse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPVclZKSzVyPUGuOVcxPDVizszN M3m4PXNCVkeHUh?=
HD-MY-Z M4\sS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK5UJdKSzVyPUGuOVc{PzZizszN M1\NOnNCVkeHUh?=
SK-MEL-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHpV5RKSzVyPUGuOVc1PTlizszN M1S4NHNCVkeHUh?=
RT-112 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\HTWM2OD1zLkW4PVUzKM7:TR?= MnzmV2FPT0WU
COLO-829 NWPwXYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwNkKyN|Ih|ryP M37Kb3NCVkeHUh?=
OVCAR-5 NIfH[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFwN{e2PFch|ryP M1nNSHNCVkeHUh?=
NB69 M4PmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjUTWM2OD1zLke4OFY6KM7:TR?= MXXTRW5ITVJ?
NCI-H292 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmWxTWM2OD1zLki2Olk6KM7:TR?= MXvTRW5ITVJ?
LOXIMVI MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXidFNFUUN3ME2xMlg6PDJ5IN88US=> NGTGTnRUSU6JRWK=
BPH-1 M3PPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG1TWM2OD1zLki5OVkyKM7:TR?= MUDTRW5ITVJ?
A375 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\vdWtKSzVyPUGuPFk4OTRizszN MlK2V2FPT0WU
LCLC-97TM1 NIG3b2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vEVmlEPTB;MT65NlI2PiEQvF2= MWTTRW5ITVJ?
RXF393 NHv5PIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\IbZJIUUN3ME2xMlk4QDh5IN88US=> NYjxNolOW0GQR1XS
HCC70 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LQXWlEPTB;Mj6wNlQzPiEQvF2= NV;FTJlRW0GQR1XS
EM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvqPZZIUUN3ME2yMlA4OTl6IN88US=> MmXNV2FPT0WU
MZ2-MEL NH;tTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrxSFU3UUN3ME2yMlEyOTJ5IN88US=> M2DK[nNCVkeHUh?=
HN NVTwbGV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwMU[yO|gh|ryP NV2yW4NQW0GQR1XS
A2058 NHz0UZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwMUmyO|kh|ryP MmGyV2FPT0WU
NB7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnkeIVIUUN3ME2yMlM1ODh4IN88US=> MWTTRW5ITVJ?
DOK Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjDRYVOUUN3ME2yMlM2Pzd|IN88US=> M17XfXNCVkeHUh?=
CAL-27 Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPSeZZ[UUN3ME2yMlM6OjN4IN88US=> MXrTRW5ITVJ?
BB65-RCC M2fGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJwNEC2O|Qh|ryP M4PlcXNCVkeHUh?=
RD MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jGfWlEPTB;Mj60OFczOyEQvF2= MnXsV2FPT0WU
KNS-62 NH65e29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj3TWM2OD1{LkWxNVY1KM7:TR?= NILMemxUSU6JRWK=
EW-13 M37aU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwNU[zN|kh|ryP M4jGZXNCVkeHUh?=
DB M4Did2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJwNUi3PFgh|ryP M4\y[HNCVkeHUh?=
HCC2218 NY\yOFhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJwNkS3O|gh|ryP NIHXd|VUSU6JRWK=
L-363 M1[wRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD1NVhJUUN3ME2yMlc1OzdizszN NUnBWm1WW0GQR1XS
CHL-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfBTWM2OD1{LkiwO|g2KM7:TR?= M4r3PXNCVkeHUh?=
BFTC-905 MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof2TWM2OD1{LkiyOVMh|ryP MmT4V2FPT0WU
HCE-T MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrGTWM2OD1{LkizNlY1KM7:TR?= NHvU[VJUSU6JRWK=
COLO-792 NEHaV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n4fGlEPTB;Mj64OFAzPyEQvF2= NYjzc2ZxW0GQR1XS
LB2241-RCC NFrhcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nVdGlEPTB;Mj64OVg6OyEQvF2= MXrTRW5ITVJ?
CAL-39 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjKTWM2OD1{Lki5PVk6KM7:TR?= M{\NO3NCVkeHUh?=
T-24 NH7Yb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHqdXBKSzVyPUKuPVEyOTJizszN NV7heINOW0GQR1XS
NCI-H727 NV3tcnZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwOUG3PVYh|ryP NUTR[ZNQW0GQR1XS
Ca9-22 NUH2N4NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[0fpNxUUN3ME2yMlk4OjV3IN88US=> NUWydpFrW0GQR1XS
MIA-PaCa-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jvfmlEPTB;Mz6wNFc5OSEQvF2= NEDM[oNUSU6JRWK=
HT-1080 MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTNwMEG5PVch|ryP NYLxXm0xW0GQR1XS
D-423MG NVqzOFVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHoSopVUUN3ME2zMlA4PzV|IN88US=> M3nrRnNCVkeHUh?=
LAMA-84 NHPKcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDGTWM2OD1|LkGzOVgh|ryP MVjTRW5ITVJ?
SW780 NXXUTZE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HRbGlEPTB;Mz6xOFIzQSEQvF2= NILMenFUSU6JRWK=
KU-19-19 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHtTWM2OD1|LkG3NFM1KM7:TR?= MkLXV2FPT0WU
COLO-741 M4i5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;CT2lEPTB;Mz6xPFY4OyEQvF2= M4rFWXNCVkeHUh?=
HSC-3 NYrJTHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jPR2lEPTB;Mz6yN|E2OSEQvF2= NWPYSlhOW0GQR1XS
SN12C MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LIXWlEPTB;Mz6yOFcxOSEQvF2= MlnsV2FPT0WU
786-0 MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PVcmlEPTB;Mz6yO|I1OyEQvF2= NHW0V2lUSU6JRWK=
GAK NF3CcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLVTWM2OD1|LkOyOVYyKM7:TR?= NW\yd4lnW0GQR1XS
PANC-03-27 M2Kx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvoUFJKSzVyPUOuN|UxPDVizszN MoC5V2FPT0WU
CTB-1 MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7KTWM2OD1|LkS3NFQ4KM7:TR?= NIOwNHNUSU6JRWK=
A427 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHYTWM2OD1|LkW5OVU3KM7:TR?= NX3WbWJvW0GQR1XS
EGI-1 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXnUpNtUUN3ME2zMlYxPTh|IN88US=> NHLPNmVUSU6JRWK=
U-2-OS MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNwNkeyOVYh|ryP NHjESmVUSU6JRWK=
NCI-SNU-5 NXKxNFZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\p[FFwUUN3ME2zMlY4PzNizszN MorUV2FPT0WU
SK-LU-1 NIOzZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLU[5RyUUN3ME2zMlY5Pzl6IN88US=> NU\uUndFW0GQR1XS
697 NHLRSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmO3TWM2OD1|Lk[5OlA{KM7:TR?= MorhV2FPT0WU
HPAF-II MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTNwN{W0PUDPxE1? M3;zdXNCVkeHUh?=
NCI-H2087 MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNwOES2O|Ih|ryP MnjuV2FPT0WU
SK-MEL-3 M2HiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNwOEWxOVQh|ryP MkXYV2FPT0WU
CGTH-W-1 NX;ES496T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNwOEW3NlUh|ryP MmnpV2FPT0WU
8505C MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrjPXlKSzVyPUOuPVAxPzhizszN MVfTRW5ITVJ?
GAMG MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrDVYRKSzVyPUSuNFI{PzdizszN NWrCclRxW0GQR1XS
SW626 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M172OWlEPTB;ND6wOFQ5KM7:TR?= MlPTV2FPT0WU
CAL-62 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1izZWlEPTB;ND6wO|Q{KM7:TR?= MYfTRW5ITVJ?
MHH-PREB-1 M4H1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjGPWZjUUN3ME20MlEzOTFzIN88US=> MXPTRW5ITVJ?
RPMI-7951 NIqxNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnGOFBKSzVyPUSuNlU2QDlizszN NXPPZ2tMW0GQR1XS
HOP-92 NIHJdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PIOWlEPTB;ND6yOVY4KM7:TR?= NVz2ZXE6W0GQR1XS
MDA-MB-231 NFzSN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi3fIo2UUN3ME20MlI6OjJ|IN88US=> MmXOV2FPT0WU
LAN-6 M4TuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nxemlEPTB;ND6zNVY{PyEQvF2= NGrOWHBUSU6JRWK=
ALL-PO M1XHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHQ[IVHUUN3ME20MlM3OTV4IN88US=> MVvTRW5ITVJ?
HH MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTRwNEG1PVch|ryP M4rLZXNCVkeHUh?=
IGROV-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTRwNEWxO|Eh|ryP MofmV2FPT0WU
NCI-H358 Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HmT2lEPTB;ND60OVM5PSEQvF2= M3rWXHNCVkeHUh?=
NB5 NXjkUZBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln4TWM2OD12Lk[wN|Y6KM7:TR?= Ml\tV2FPT0WU
NCI-H747 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInzc4VKSzVyPUSuOlg5ODdizszN MnXyV2FPT0WU
NH-12 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTRwN{G2NlUh|ryP MUnTRW5ITVJ?
LB1047-RCC NGL4SlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTRwN{O4NVUh|ryP NIDtdplUSU6JRWK=
EFO-27 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTRwN{i2Olch|ryP MY\TRW5ITVJ?
EPLC-272H NVnMXox3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITQeoJKSzVyPUSuPVk3PjlizszN MXzTRW5ITVJ?
CAL-54 NG\Je2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD1PJEzUUN3ME21MlAzPjl3IN88US=> NVfxXVhIW0GQR1XS
H4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfuOVZKSzVyPUWuNFQzPTVizszN MljsV2FPT0WU
MOLT-13 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPLZnJOUUN3ME21MlA3Pzd4IN88US=> NV;CeFNKW0GQR1XS
CAL-33 M{LvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTVwMUKzNVch|ryP MVXTRW5ITVJ?
23132-87 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7wNVVpUUN3ME21MlE3QDd{IN88US=> MoHiV2FPT0WU
UM-UC-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTVwMUiwOFch|ryP M3jhNHNCVkeHUh?=
HuH-7 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTVwMkexOFch|ryP NILhNYRUSU6JRWK=
BCPAP NV\WZZVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDtS|BCUUN3ME21MlMzQTZ7IN88US=> NFWyPW5USU6JRWK=
AsPC-1 M4X2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\qTWM2OD13LkO2O|Y{KM7:TR?= M{n3[XNCVkeHUh?=
NCI-H1155 M2W2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGGwUnVKSzVyPUWuOFAxPTFizszN M2P0V3NCVkeHUh?=
GT3TKB NYm5fGFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTVwNE[1PVgh|ryP NHG5PGhUSU6JRWK=
HCC2998 M{PLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjSfVJKSzVyPUWuOFkyODlizszN NULNZ3F6W0GQR1XS
NUGC-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\YTWM2OD13LkS5N|AzKM7:TR?= NULpSVV1W0GQR1XS
Hs-578-T NWr4cXRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTVwNUO3PVQh|ryP MX7TRW5ITVJ?
FADU M{G5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f6Z2lEPTB;NT61OVczPiEQvF2= M17wfnNCVkeHUh?=
NBsusSR MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTVwNUexOVUh|ryP M3;6[XNCVkeHUh?=
ME-180 NFH4WnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfDeYFMUUN3ME21MlU5ODl{IN88US=> M2fFdHNCVkeHUh?=
SW1710 M2TPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT4dIJKSzVyPUWuOlE3PTRizszN MnLaV2FPT0WU
HuP-T3 M3HwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDMTWM2OD13Lk[yNFI6KM7:TR?= MVPTRW5ITVJ?
HOS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CxSWlEPTB;NT62NlkzOyEQvF2= M{DDW3NCVkeHUh?=
PA-1 NWTIcox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO3TWM2OD13Lk[0NlY2KM7:TR?= MULTRW5ITVJ?
LU-99A M3XYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzJTWM2OD13Lk[2OFUyKM7:TR?= MknEV2FPT0WU
RS4-11 NGj4NXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInHdZVKSzVyPUWuOlY4PzVizszN M1HrVnNCVkeHUh?=
TE-8 NWXKZ5lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTVwNki1N|ch|ryP NGm5Tm9USU6JRWK=
RERF-LC-MS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHtTWM2OD13Lk[4PFA{KM7:TR?= MUXTRW5ITVJ?
MEL-JUSO NY\wc2FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O1[WlEPTB;NT63N|c5KM7:TR?= NULYeFRJW0GQR1XS
SK-MES-1 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTVwOEO1Nlgh|ryP M1ywNnNCVkeHUh?=
D-263MG NXrLcFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq2TWM2OD13Lki4N|UyKM7:TR?= M3nUUXNCVkeHUh?=
NB10 M4LBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i3SGlEPTB;NT64PVQ3KM7:TR?= MmDHV2FPT0WU
SK-HEP-1 NF3hVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPyVFh1UUN3ME21Mlk{PDdzIN88US=> M3HyN3NCVkeHUh?=
HT-29 MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjv[VdHUUN3ME21Mlk5OTF6IN88US=> MnHEV2FPT0WU
KYSE-140 M1jVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Xi[mlEPTB;Nj6wNlE5OiEQvF2= MWjTRW5ITVJ?
NCI-H1666 NHPGWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj4e4prUUN3ME22MlA5PDZzIN88US=> M3jDe3NCVkeHUh?=
NCI-H1304 M37abWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf6NVhKSzVyPU[uNVk6PCEQvF2= NEHTcVFUSU6JRWK=
RPMI-8866 M1vwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvFZ4k3UUN3ME22MlIyOzF|IN88US=> M1;TR3NCVkeHUh?=
MV-4-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\vXoNKSzVyPU[uNlMyQTlizszN MXzTRW5ITVJ?
A431 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGWxOm9KSzVyPU[uNlQzQTZizszN MkPYV2FPT0WU
PANC-10-05 NIT6OHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKz[YZKSzVyPU[uNlg{PjNizszN NESwRlJUSU6JRWK=
TK10 NH\jOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLY[4VKSzVyPU[uN|I3ODRizszN M1HnbXNCVkeHUh?=
NCI-H1975 M{jKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfzTWM2OD14LkS3NlE2KM7:TR?= M{\2VnNCVkeHUh?=
A172 NFjYemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjlTG9LUUN3ME22MlQ6OTd4IN88US=> MVPTRW5ITVJ?
D-566MG NHjWUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWKwTZdJUUN3ME22MlU1OzB|IN88US=> NXvPSnpzW0GQR1XS
NCI-H2122 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe3fIs{UUN3ME22MlYyPTJ6IN88US=> MnfOV2FPT0WU
COR-L105 M{jJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTZwNkWyO|Uh|ryP NVT5V5V4W0GQR1XS
AN3-CA NGL6Z25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTZwNki2OFEh|ryP NYm1Z2p{W0GQR1XS
Calu-6 M4HHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ufVVKSzVyPU[uO|k3QThizszN NVLo[FJwW0GQR1XS
HCT-116 NXm1WoVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTZwOEGyOlQh|ryP NGXwenBUSU6JRWK=
MHH-NB-11 NX7qWmdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\4[lUyUUN3ME22Mlg2ODB{IN88US=> NH7YfoZUSU6JRWK=
MFE-280 NI\6cWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTZwOEW5PFMh|ryP M2HaOHNCVkeHUh?=
SW1088 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHm5bGpKSzVyPU[uPVE6OTNizszN MXfTRW5ITVJ?
SW48 M2DmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zoemlEPTB;Nj65OFUyKM7:TR?= NImyOY1USU6JRWK=
HuCCT1 MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\hSWZKSzVyPUeuNFExOzdizszN NFT1XGtUSU6JRWK=
ACHN Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK4UXB2UUN3ME23MlAzQTR|IN88US=> MnK5V2FPT0WU
8305C NEH2ZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTdwMEm5PVUh|ryP M3P4Z3NCVkeHUh?=
DoTc2-4510 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTdwMUKxOUDPxE1? MVrTRW5ITVJ?
COR-L23 NVv3dGo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjGU|RKSzVyPUeuNlQ1OiEQvF2= MkTqV2FPT0WU
SK-MEL-30 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnSyTWM2OD15LkK1NFg{KM7:TR?= MnzaV2FPT0WU
BE-13 NX3Vc2k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXP2SZJsUUN3ME23MlM{QDN2IN88US=> NGPse5JUSU6JRWK=
GR-ST M3:5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHrTWM2OD15LkSwNVc1KM7:TR?= MXLTRW5ITVJ?
LU-135 MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTdwNUW5N|kh|ryP Mk\kV2FPT0WU
U-266 M{ntcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH3TWM2OD15LkW2Nlg3KM7:TR?= NIWxNG5USU6JRWK=
NCI-H1355 NHnOZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTdwNUi2N|Uh|ryP MlLYV2FPT0WU
NB14 MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nFdGlEPTB;Nz62OlY1OiEQvF2= NVHHU4ZGW0GQR1XS
SCC-25 M{DVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M362SGlEPTB;Nz63NFkh|ryP NFrpT4lUSU6JRWK=
COLO-678 M3zVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTdwN{GwO|Yh|ryP Mo[xV2FPT0WU
TGBC1TKB NGrW[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLpTWM2OD15Lki5N|k5KM7:TR?= NFKzcFNUSU6JRWK=
IST-MEL1 NGLifG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmwTWM2OD16LkCwOFA3KM7:TR?= MYTTRW5ITVJ?
ECC10 M1Owbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTlN4E{UUN3ME24MlA{Ozl3IN88US=> NFX6N2JUSU6JRWK=
EW-16 M13uR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzWTWM2OD16LkC4OFQ2KM7:TR?= MlLOV2FPT0WU
DOHH-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn0b3lKSzVyPUiuNlAxQTVizszN M1jte3NCVkeHUh?=
NCI-H1581 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRThwMk[zNlMh|ryP M1v2bnNCVkeHUh?=
TE-5 NX7SUIhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRThwNEK0Nlkh|ryP M2\RRXNCVkeHUh?=
CAKI-1 NETKdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3zdVNRUUN3ME24MlU4OjJ{IN88US=> M{HoNHNCVkeHUh?=
A673 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfiOWVUUUN3ME24MlY{OjB{IN88US=> M3fjcXNCVkeHUh?=
CAL-12T M{HYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rJRmlEPTB;OD62OVc2OyEQvF2= M{TQZnNCVkeHUh?=
DBTRG-05MG NGXWVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTXSmhKSzVyPUiuO|Q5PTlizszN M2DRe3NCVkeHUh?=
SK-N-FI MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17OdmlEPTB;OD64NVM4QSEQvF2= MnTOV2FPT0WU
K-562 NFK2[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRThwOEO5OVch|ryP MljjV2FPT0WU
SBC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG2TWM2OD16Lki2OlQ2KM7:TR?= NGDacIJUSU6JRWK=
ES4 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRThwOE[4PFQh|ryP NYLZdopWW0GQR1XS
MS-1 NGnwbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRThwOEe1NVch|ryP MlfEV2FPT0WU
RKO MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PrO2lEPTB;OD64PVA2PyEQvF2= NELIeHZUSU6JRWK=
NCI-H1693 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuyToNKSzVyPUiuPVIyPyEQvF2= MnztV2FPT0WU
SW954 M3HEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRThwOU[5O|gh|ryP NIrSUZFUSU6JRWK=
SK-UT-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDZWYFKSzVyPUiuPVc3QDNizszN NWe5Wm97W0GQR1XS
T98G M{S1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRThwOUm4OFYh|ryP MVjTRW5ITVJ?
NCI-H2126 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnrfldEUUN3ME25MlAxQDJ4IN88US=> MkCwV2FPT0WU
TE-12 M3vNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HRNmlEPTB;OT6wN|M3PyEQvF2= M{fQd3NCVkeHUh?=
DK-MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDLTWM2OD17LkKxNVkyKM7:TR?= MYPTRW5ITVJ?
MEG-01 M2\0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\ncWlEPTB;OT6yOFk{OSEQvF2= M1jWS3NCVkeHUh?=
HCC1937 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPxTWM2OD17LkK5NFkyKM7:TR?= MUDTRW5ITVJ?
MKN45 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXyTWM2OD17LkS1NFY2KM7:TR?= M4XPV3NCVkeHUh?=
NCI-H1792 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSyWGdHUUN3ME25MlQ2OjF7IN88US=> MUHTRW5ITVJ?
SW1417 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELqdWtKSzVyPUmuOVY5OzdizszN Ml;3V2FPT0WU
639-V NXflSW9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXmTWM2OD17Lk[0N|g5KM7:TR?= M3nQ[nNCVkeHUh?=
P30-OHK MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\wTWM2OD17Lk[1N|E3KM7:TR?= MmLSV2FPT0WU
YKG-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TLZmlEPTB;OT63OVA{OyEQvF2= MlvIV2FPT0WU
KGN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXZSW1KSzVyPUmuPFM4QTVizszN MmXIV2FPT0WU
MSTO-211H NVz6dIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHObnlKSzVyPUmuPVU2OjlizszN M{LubHNCVkeHUh?=
NCI-H1573 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFyLkG1O|Qh|ryP NXvxVWJ2W0GQR1XS
NCI-H720 MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfHNVhKSzVyPUGwMlE6QDlizszN NWrDTI1kW0GQR1XS
KARPAS-45 MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvWTWM2OD1zMD6yO|k2KM7:TR?= NHzZe2dUSU6JRWK=
MDA-MB-175-VII NW\5T4VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K4PWlEPTB;MUCuOFgh|ryP NETjVGtUSU6JRWK=
SK-NEP-1 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7oTWM2OD1zMD60PVgyKM7:TR?= NXvvWIJ4W0GQR1XS
MKN28 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfLTWM2OD1zMD61NVgh|ryP MnnIV2FPT0WU
KYSE-520 NILqdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zIW2lEPTB;MUCuOVIh|ryP NG\SdoZUSU6JRWK=
KE-37 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjBfYlDUUN3ME2xNE42Ojd{IN88US=> MmXtV2FPT0WU
VA-ES-BJ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFyLkW2O{DPxE1? M2nLXHNCVkeHUh?=
CCRF-CEM MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDn[WZ{UUN3ME2xNE42Pjh2IN88US=> M4HDfHNCVkeHUh?=
GMS-10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFyLk[wPVQh|ryP MoGxV2FPT0WU
NCI-H1623 NGT4WHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;wTWM2OD1zMD62N|c6KM7:TR?= NGC4UpBUSU6JRWK=
NEC8 MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFyLke3O|Mh|ryP MlLjV2FPT0WU
MOLT-16 NHLneGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjDbJNKSzVyPUGwMlgyOTNizszN M{K1eXNCVkeHUh?=
DJM-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFzLkCzO|kh|ryP NX6xepNRW0GQR1XS
U251 M2e0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvPR2RKSzVyPUGxMlA1OiEQvF2= MoTlV2FPT0WU
SBC-5 NXHjTGNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFzLkG0Olch|ryP NXfzU5c2W0GQR1XS
SW756 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y2S2lEPTB;MUGuNlE2PCEQvF2= MlzLV2FPT0WU
KS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULRZZdNUUN3ME2xNU4zPjF7IN88US=> MVnTRW5ITVJ?
SF295 M1;OUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofXTWM2OD1zMT6zNVA1KM7:TR?= NG\UTlJUSU6JRWK=
YH-13 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGWx[otKSzVyPUGxMlMzPjdizszN M4TMV3NCVkeHUh?=
SW837 NEnNOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLVTWM2OD1zMT6zOVA3KM7:TR?= M{\0SXNCVkeHUh?=
KYSE-450 NVPubo1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFzLkSwOVch|ryP MVPTRW5ITVJ?
KYSE-180 M4DNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH0TWM2OD1zMT60PFIh|ryP M3XxZnNCVkeHUh?=
S-117 NIPCbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LDZ2lEPTB;MUGuOFg6PiEQvF2= Mn;wV2FPT0WU
KOSC-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFzLk[yNlIh|ryP NFjEd4dUSU6JRWK=
KYSE-270 NYHkWXdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DaeGlEPTB;MUGuPFc1PSEQvF2= M2C5WHNCVkeHUh?=
D-336MG NVTWd3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Ll[GlEPTB;MUGuPVA4PSEQvF2= NWHlOWVQW0GQR1XS
KALS-1 NHP6R2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS0TWM2OD1zMj6wNFE3KM7:TR?= MlvKV2FPT0WU
LB373-MEL-D NXvJc3F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n4b2lEPTB;MUKuNFU{OyEQvF2= MlT6V2FPT0WU
HLE NHS1XpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKyTWM2OD1zMj6wOVg2KM7:TR?= NU\te4hNW0GQR1XS
SJSA-1 M3zMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF{LkC3N|Uh|ryP NWXFd4wyW0GQR1XS
SW1990 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTab3hQUUN3ME2xNk4xQTFzIN88US=> MX3TRW5ITVJ?
NOS-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqwTWM2OD1zMj6xN|UzKM7:TR?= NGDq[oNUSU6JRWK=
GI-ME-N MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3hfJdKSzVyPUGyMlIyPjNizszN M4jqNnNCVkeHUh?=
NCI-H1703 NXS0ZlVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLEc5JYUUN3ME2xNk4zPjF4IN88US=> NVG0S5B[W0GQR1XS
ES7 NGL2cWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF{LkK3NlQh|ryP MnSxV2FPT0WU
KYSE-510 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF{LkWwO|kh|ryP MmjSV2FPT0WU
BHY M3LmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXldGhbUUN3ME2xNk42OzB5IN88US=> MVTTRW5ITVJ?
TCCSUP M1fm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjIPHNKSzVyPUGyMlU4PTdizszN M2mxdnNCVkeHUh?=
HSC-2 NFfjUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3YXVFSUUN3ME2xNk42QTl4IN88US=> MmHlV2FPT0WU
BEN MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fUSmlEPTB;MUKuOlE1OyEQvF2= NVvDZ4YyW0GQR1XS
769-P NUDsOZFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\mTWlEPTB;MUKuO|kzPCEQvF2= NVjnPXBJW0GQR1XS
HT M4rVWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTzRZZFUUN3ME2xNk45OzR4IN88US=> NEXwT|NUSU6JRWK=
LXF-289 NWnaWXlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDx[2NKSzVyPUGyMlk2OzFizszN Mkm3V2FPT0WU
OVCAR-3 NF3JcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PE[mlEPTB;MUKuPVU3PyEQvF2= MYDTRW5ITVJ?
ATN-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDjTnpmUUN3ME2xN{4xOTh2IN88US=> MX7TRW5ITVJ?
8-MG-BA NX3ORolET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G1[WlEPTB;MUOuNFQ2PSEQvF2= NXzE[5RIW0GQR1XS
SW13 NXmyR5Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF|LkGxOlUh|ryP NX7hbJJYW0GQR1XS
NCI-H1092 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILjcmNKSzVyPUGzMlE3OiEQvF2= MUfTRW5ITVJ?
OAW-42 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSwd2xKSzVyPUGzMlE6OzdizszN M3GwPHNCVkeHUh?=
NCI-H2452 M2jVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojkTWM2OD1zMz6yNVc2KM7:TR?= Mo\jV2FPT0WU
CAPAN-1 M1jsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF|LkW1NVQh|ryP MofGV2FPT0WU
NCI-H2009 NVm0WFFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnnTWM2OD1zMz61PVE6KM7:TR?= M2rrXXNCVkeHUh?=
SF268 NWjud|gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF|Lk[zNlYh|ryP MXLTRW5ITVJ?
GCIY NYnxW446T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HQ[GlEPTB;MUOuOlkzPyEQvF2= MV3TRW5ITVJ?
OS-RC-2 M{XBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLVTWM2OD1zMz65OVAyKM7:TR?= MmPuV2FPT0WU
GCT MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrpdGRKSzVyPUGzMlk3QTdizszN NXjmUFlNW0GQR1XS
NB17 NIf4eYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDkN2hKSzVyPUG0MlA5PSEQvF2= MoPkV2FPT0WU
NCI-H2030 MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrmTWM2OD1zND6xOFY2KM7:TR?= NFqwXnBUSU6JRWK=
HC-1 M4q2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vYXWlEPTB;MUSuNlA5PyEQvF2= MlG5V2FPT0WU
QIMR-WIL Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF2LkO0NVIh|ryP Mn7sV2FPT0WU
Capan-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHpTWM2OD1zND6zO|E1KM7:TR?= MUjTRW5ITVJ?
BALL-1 M4\X[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TKSGlEPTB;MUSuOFY3PSEQvF2= NV2zb2tEW0GQR1XS
LS-1034 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qxU2lEPTB;MUSuOlE2OiEQvF2= MUjTRW5ITVJ?
U-118-MG M3Lye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITZOnhKSzVyPUG0MlY{OSEQvF2= M2C2b3NCVkeHUh?=
NCI-H630 M4L6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC4RVNKSzVyPUG0MlY2PjhizszN MnjQV2FPT0WU
OVCAR-8 NUfRZ45ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fuW2lEPTB;MUSuO|IxOSEQvF2= M13qfXNCVkeHUh?=
NCI-H2347 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PaNWlEPTB;MUSuPFI{KM7:TR?= MX;TRW5ITVJ?
BT-549 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLDO5pKSzVyPUG0MlgzQDRizszN MUPTRW5ITVJ?
LB831-BLC NW[zNI1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\GeGlEPTB;MUSuPFk{PCEQvF2= MlHMV2FPT0WU
NCI-H661 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF2Lkm1PUDPxE1? MnrRV2FPT0WU
MKN7 M3;ZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7R[5NKSzVyPUG1MlAxQTNizszN NHHtWFJUSU6JRWK=
U-87-MG MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF3LkC4PVch|ryP MmnIV2FPT0WU
OVCAR-4 NXLEZlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;pNVFKSzVyPUG1MlE1OjRizszN NXviXGlmW0GQR1XS
OE33 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC5Zms6UUN3ME2xOU4yPzFzIN88US=> NILRdGZUSU6JRWK=
EC-GI-10 M4TGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nmfGlEPTB;MUWuNlM2PyEQvF2= NV3sb2RKW0GQR1XS
AM-38 NYnaZYFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF3LkK3NVch|ryP NG\Jc2JUSU6JRWK=
NCI-H1563 M2DST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfFbWRKSzVyPUG1MlM1QSEQvF2= MkjKV2FPT0WU
SCC-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jQRWlEPTB;MUWuOFExOyEQvF2= MkDrV2FPT0WU
Detroit562 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\jTWM2OD1zNT60OVQ4KM7:TR?= MV7TRW5ITVJ?
PC-14 M{PLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlznTWM2OD1zNT60PFY3KM7:TR?= MYnTRW5ITVJ?
ES3 M2nEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7iW4VnUUN3ME2xOU42OzZizszN Mk\3V2FPT0WU
OCI-AML2 MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPaNFVKSzVyPUG1Mlc3OTRizszN NYDVOWFkW0GQR1XS
LU-134-A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF3LkmwNVgh|ryP MX;TRW5ITVJ?
SAS NF\NNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTKcXpFUUN3ME2xOU46Ozd|IN88US=> NGGzXZlUSU6JRWK=
TGBC11TKB M2XNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHZTWM2OD1zNT65OFE1KM7:TR?= NWf1bG9PW0GQR1XS
HOP-62 MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL4O3BsUUN3ME2xOU46PTl5IN88US=> M3LxbHNCVkeHUh?=
G-401 NHvXe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDrTWM2OD1zNT65OlQ6KM7:TR?= NXHRVlF1W0GQR1XS
NCI-H28 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TuTGlEPTB;MU[uNFg2PiEQvF2= NGLWPXdUSU6JRWK=
A204 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XyWWlEPTB;MU[uNlAxPiEQvF2= MlX0V2FPT0WU
NCI-H1299 M{D6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TxfWlEPTB;MU[uNlI6OSEQvF2= NV:xZlg2W0GQR1XS
VMRC-RCZ NEP2WmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C4NWlEPTB;MU[uNlU6OiEQvF2= MnLYV2FPT0WU
BxPC-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF4LkK4OVYh|ryP MmW2V2FPT0WU
NCI-H2228 NHzEPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF4LkWxOVgh|ryP NH;ndIRUSU6JRWK=
NCI-H23 NFm2UIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH2Tnd[UUN3ME2xOk43ODd6IN88US=> NGPifldUSU6JRWK=
NKM-1 M{TlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfFPYZzUUN3ME2xO{4xOTh7IN88US=> MX;TRW5ITVJ?
KYSE-70 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO3TWM2OD1zNz6yPFkh|ryP MoLiV2FPT0WU
BB49-HNC M4Hvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[2UXJpUUN3ME2xO{42Pjh4IN88US=> NUHqdGk5W0GQR1XS
SCC-15 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf3fVJ6UUN3ME2xO{45PDd|IN88US=> NFLOdZFUSU6JRWK=
D-247MG Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF5LkmyOFch|ryP MWPTRW5ITVJ?
BB30-HNC M2nSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\DbWlEPTB;MUiuNFMyQCEQvF2= NGnkbnZUSU6JRWK=
CAL-85-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4dJdtUUN3ME2xPE4yQDB7IN88US=> NUnFTGh7W0GQR1XS
HT-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor4TWM2OD1zOD6zPVc4KM7:TR?= MlPYV2FPT0WU
KYSE-410 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLhOolKSzVyPUG4MlQ2PzdizszN NGX5XWlUSU6JRWK=
SW982 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF6LkW2OFkh|ryP NFfjbWlUSU6JRWK=
SW962 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF6LkW3NFIh|ryP M3;neHNCVkeHUh?=
Ramos-2G6-4C10 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\qdms2UUN3ME2xPE42QTJ5IN88US=> NYDFZ21EW0GQR1XS
OC-314 M4TvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF6LkezPFQh|ryP MmXDV2FPT0WU
LS-123 Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInqWXlKSzVyPUG4Mlc6ODFizszN MkPDV2FPT0WU
D-502MG NVTyXGh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn1T29NUUN3ME2xPE45OTN7IN88US=> M3zoNHNCVkeHUh?=
RO82-W-1 NXf3UYs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF6LkiyPFgh|ryP MnexV2FPT0WU
HuO9 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojPTWM2OD1zOT6xN|c6KM7:TR?= NGPNNG9USU6JRWK=
ETK-1 NFr2c4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TlU2lEPTB;MUmuNVgzPyEQvF2= MVPTRW5ITVJ?
SNU-387 Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7vdWdKSzVyPUG5MlE5QDlizszN MX\TRW5ITVJ?
SW1573 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH75[4dKSzVyPUG5MlE6PjlizszN NFzYcGhUSU6JRWK=
NTERA-S-cl-D1 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF7LkKwNFch|ryP M4e0VXNCVkeHUh?=
SF126 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID1UYxKSzVyPUG5MlM2ODJizszN M4LNenNCVkeHUh?=
Calu-3 M1noZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTVTWM2OD1zOT60NlM4KM7:TR?= MkL5V2FPT0WU
NCI-H1048 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJyLkOyOlYh|ryP Ml[xV2FPT0WU
NCI-H226 NGnNT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLqcmI2UUN3ME2yNE41Ozl7IN88US=> M4LrbXNCVkeHUh?=
FTC-133 NV7jSGM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJyLkS3NFMh|ryP NWfkOlBXW0GQR1XS
SF539 NXv0[G1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf0TWM2OD1{MD61NVczKM7:TR?= M3TCe3NCVkeHUh?=
TE-6 NXX1fVd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJyLkiwOlch|ryP NYTxZXFoW0GQR1XS
UMC-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJyLkmxOlQh|ryP NEnzUoJUSU6JRWK=
Becker NH7ze4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHo[GVKSzVyPUKxMlEyOThizszN NFrS[FNUSU6JRWK=
KP-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjGfYhlUUN3ME2yNU4yOTl4IN88US=> MXHTRW5ITVJ?
ChaGo-K-1 NIXDflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrpWZRKSzVyPUKxMlM3OjdizszN NFizfWlUSU6JRWK=
CFPAC-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPFNJZKSzVyPUKxMlM5PThizszN NHS0RVlUSU6JRWK=
A498 NILnWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\iTWM2OD1{MT61N|EzKM7:TR?= M4W3UnNCVkeHUh?=
NCI-H1755 NF32UWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu2TWM2OD1{MT62O|QyKM7:TR?= MkPyV2FPT0WU
TI-73 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ{LkOyPEDPxE1? MmrGV2FPT0WU
NCI-H441 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\qTmlEPTB;MkKuOVY5QSEQvF2= M{HJTXNCVkeHUh?=
CaR-1 NEfZXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:2TWM2OD1{Mz6wNlE{KM7:TR?= NFL0[3FUSU6JRWK=
HCC1806 M3PKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;VTWM2OD1{Mz6wOVg{KM7:TR?= NUL2U4VuW0GQR1XS
SNU-449 MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TxO2lEPTB;MkOuN|I6KM7:TR?= MWPTRW5ITVJ?
EKVX NUi5ZXBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z5XmlEPTB;MkOuN|kxQSEQvF2= MljUV2FPT0WU
DMS-114 NVzqWYc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3iTWM2OD1{Mz61O|Y2KM7:TR?= MoOyV2FPT0WU
A704 NHzvcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjzTWM2OD1{Mz62NVA{KM7:TR?= M4rae3NCVkeHUh?=
LC-2-ad MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLZ[VE6UUN3ME2yN{43OTR5IN88US=> MoDkV2FPT0WU
VM-CUB-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L5R2lEPTB;MkOuO|M1OSEQvF2= Mmn6V2FPT0WU
PC-3 NWjjTXc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHZZpN3UUN3ME2yOE4xPTJ4IN88US=> NV7h[XVJW0GQR1XS
HEL NV3zWWduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PlVGlEPTB;MkSuNFg3PSEQvF2= M2W3RnNCVkeHUh?=
ABC-1 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjne2RQUUN3ME2yOE4zPzJ7IN88US=> MXLTRW5ITVJ?
COLO-680N M3;jTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W1PWlEPTB;MkSuOFc3PCEQvF2= M3G3SnNCVkeHUh?=
MZ1-PC Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJ2Lk[4O{DPxE1? MmSzV2FPT0WU
NCI-H69 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4KydGlEPTB;MkSuO|M2PCEQvF2= NYn1R3d5W0GQR1XS
TE-1 M4\yc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICx[YVKSzVyPUK1MlA1QTlizszN MlTlV2FPT0WU
EW-3 NVi0W3U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;yTWM2OD1{NT6xNVMh|ryP MnXyV2FPT0WU
PANC-08-13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ3LkixNFMh|ryP M2D6ZnNCVkeHUh?=
NMC-G1 MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DvT2lEPTB;Mk[uNFA5QCEQvF2= MkTpV2FPT0WU
BT-20 NIDvUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojJTWM2OD1{Nj60OVQ{KM7:TR?= NGDqW2FUSU6JRWK=
TGBC24TKB NYjYcJhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmzTWM2OD1{Nj63N|MyKM7:TR?= NXHxbGZtW0GQR1XS
TE-11 NXLVeFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJ4Lkm4PVUh|ryP M3ryfnNCVkeHUh?=
ESS-1 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHYUWU2UUN3ME2yO{4{OjF4IN88US=> MlTaV2FPT0WU
JVM-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG2TWM2OD1{Nz62OFc2KM7:TR?= NGjTelFUSU6JRWK=
C3A NGD0XlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrEZ5lKSzVyPUK3Mlg1QTZizszN NWXUNYI5W0GQR1XS
MDA-MB-157 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTqZ5p3UUN3ME2yO{45PzV|IN88US=> NXvSNIRFW0GQR1XS
KLE MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJ6LkGwOVgh|ryP NVywUnMxW0GQR1XS
ES1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLyZXQ3UUN3ME2yPE4yQDN6IN88US=> MX\TRW5ITVJ?
CAL-120 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDrTWM2OD1{OD6zPVk6KM7:TR?= NWLvcJNpW0GQR1XS
NCI-N87 MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nuV2lEPTB;MkiuOVExPSEQvF2= NV7se3BSW0GQR1XS
RPMI-8226 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLPbG5zUUN3ME2yPU4yQDR|IN88US=> NYDySJBPW0GQR1XS
COR-L88 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ7LkK0NVkh|ryP NGWzXHVUSU6JRWK=
UACC-893 NWfPNoRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XJOmlEPTB;MkmuN|E{PyEQvF2= M1LOSHNCVkeHUh?=
C8166 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37rdGlEPTB;MkmuPVk6PiEQvF2= NFvwemVUSU6JRWK=
J82 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfGSIhKSzVyPUOwMlgyPDdizszN M1HnbHNCVkeHUh?=
PFSK-1 NGXTWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTVTWM2OD1|MT6wOlU6KM7:TR?= MmTSV2FPT0WU
COLO-684 NXfhZ3F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHNUG5KSzVyPUOxMlQ{PzRizszN MlOzV2FPT0WU
CAL-72 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S3U2lEPTB;M{GuOVczQSEQvF2= NXP5XYhNW0GQR1XS
SNB75 NIexUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfpTWM2OD1|MT64PVch|ryP M1\XZXNCVkeHUh?=
MDA-MB-415 M2n2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNzLkm3OlIh|ryP MmDqV2FPT0WU
SiHa MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvBTWM2OD1|Mj60O|EyKM7:TR?= M1XmTXNCVkeHUh?=
NCI-H1648 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN{LkmzOFUh|ryP NH:zNZZUSU6JRWK=
EFO-21 NW\mZ3N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\aXmd3UUN3ME2zN{4xODVizszN MnjEV2FPT0WU
HCC38 NUCwe3dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTN|LkO4OFEh|ryP NGDpOGNUSU6JRWK=
IA-LM MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TsPGlEPTB;M{OuO|g5QSEQvF2= NWXTbHI2W0GQR1XS
CTV-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTN|Lkm3PFYh|ryP M4XUVnNCVkeHUh?=
NCI-H446 M1LIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjSWnNqUUN3ME2zOE4zPjh7IN88US=> NH;PfFFUSU6JRWK=
IST-SL1 MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCyU2MzUUN3ME2zOE44PDB6IN88US=> MVnTRW5ITVJ?
EW-22 NHTQem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjrWoxKSzVyPUO0Mlc4PTlizszN NX;CcGZOW0GQR1XS
JEG-3 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Pt[GlEPTB;M{[uNVc3PiEQvF2= M1;qcHNCVkeHUh?=
LU-65 NVHzXVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfuTWM2OD1|Nj6yPVg2KM7:TR?= M4XRe3NCVkeHUh?=
NCI-H596 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzBNo9KSzVyPUO2Mlk2QTFizszN NVHL[Yk1W0GQR1XS
KNS-81-FD NELJboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN5LkG0OUDPxE1? M4rpPXNCVkeHUh?=
NCI-H1793 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTIOmZKSzVyPUO3MlcxQDZizszN Mn3nV2FPT0WU
NCI-H460 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf1[FRYUUN3ME2zPE4xQDd|IN88US=> MUXTRW5ITVJ?
MPP-89 NYjOfFJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfHTWM2OD1|OT61PFg3KM7:TR?= NIXqe3JUSU6JRWK=
D-542MG M3zVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrQTWM2OD1|OT64OFM3KM7:TR?= NUi5O2RXW0GQR1XS
JAR Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL4TYZKSzVyPUSwMlQ4ODVizszN NFrSZmtUSU6JRWK=
NCI-H209 M1O1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTRyLk[3O{DPxE1? MYLTRW5ITVJ?
G-402 M1HBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi5UY03UUN3ME20NU4{QTl|IN88US=> NH74TodUSU6JRWK=
IST-MES1 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR{LkG5N|Uh|ryP NGm3XmVUSU6JRWK=
Daoy NF\jeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHrTWM2OD12Mj61OFcyKM7:TR?= M4D1SHNCVkeHUh?=
EW-11 NViwZ28{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4eybWlEPTB;NEOuNVIyOSEQvF2= NHvMUWNUSU6JRWK=
Saos-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1znR2lEPTB;NEOuNVU{PyEQvF2= M{TSO3NCVkeHUh?=
no-10 M1nTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnryTWM2OD12Mz6xO|AzKM7:TR?= NW\LUGxPW0GQR1XS
HCC1395 M1rKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTR|LkS2OFQh|ryP Ml;FV2FPT0WU
HCE-4 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fiNmlEPTB;NEOuO|Y3PCEQvF2= MX;TRW5ITVJ?
EW-1 NVPiXpE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTR|LkiwOFkh|ryP MWXTRW5ITVJ?
OCUB-M M4nobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETCOnVKSzVyPUS0MlM3OzhizszN M{\ZN3NCVkeHUh?=
IGR-1 NWe5SWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTR2LkSxNVUh|ryP M{XiW3NCVkeHUh?=
NCI-H1838 NIHLXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID0OZdKSzVyPUS0MlQ{PDlizszN MX7TRW5ITVJ?
NCI-H2405 NW[5U5V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTR2LkWzOEDPxE1? NIC1SnZUSU6JRWK=
GB-1 M{PpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTR2Lke0OlMh|ryP Mnu5V2FPT0WU
MG-63 NGL3T3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPxTWM2OD12Nj6wOlk3KM7:TR?= NY\aWnczW0GQR1XS
KP-N-YN NYDhcnVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTR4LkS2O|kh|ryP MonHV2FPT0WU
no-11 NGLtcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH4ZZRCUUN3ME20O{4xOjR2IN88US=> NXThfXY3W0GQR1XS
SW948 M4jHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTR5LkOzO|ch|ryP NYPoOoFDW0GQR1XS
CAMA-1 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZRWlEPTB;NEeuN|Q{QCEQvF2= MVzTRW5ITVJ?
HCC1187 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTR5LkWxJO69VQ>? MljRV2FPT0WU
D-392MG NXvWTXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmewTWM2OD12Nz62OVE3KM7:TR?= NY\meGdFW0GQR1XS
647-V NELQW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrWUGpWUUN3ME20PU4{PDF2IN88US=> MmnaV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol, pH 9
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID